Amendment to the claims

This listing of claims replaces all prior versions and listing of claims in the application. Please cancel claims 1-20 without prejudice and add claims 21-36.

In the Claims:

~~1. (Original) Use of PDE4 for identifying a compound which inhibits atherosclerosis or restenosis.~~

~~2. (Original) The use fo claim 1, wherein the PDE4 is PDE4D.~~

~~3. (Original) The use of claim 2 wherein the PDE4D is PDE4D5 or PDE4D7.~~

~~4. (Original) The use of claim 2 wherein the PDE4D is PDE4D7.~~

~~5. (Original) The sue of any of claims 1 to 4, wherein said compound inhibits Peripheral Arterial Occlusive Disease.~~

~~6. (Original) A process for identifying and obtaining a compound for therapy of atherosclerosis or restenosis, said process comprising measuring the activation or inhibition of the phosphodiesterase activity of PDE4.~~

~~7. (Original) The process of claim 6, wherein said PDE4 is PDE4D.~~

~~8. (Original) The process of claim 7 wherein te PDE4D is PDE4D5 or PDE4D7.~~

~~9. (Original) The process of claim 7 wherein the PDE4D is PDE4D7.~~

~~10. (Original) The process of any one o claims 6 to 9, wherein a compound is obtained for the treatment of Peripheral Arterial Occlusive Disease.~~

~~11. (Original) A process for identifying and obtaining a compound for therapy of atherosclerosis, or restenosis, said process comprising administering a compound suspected to be an activator or inhibitor of PDE4 to an animal in which atherosclerosis or restenosis is induced, and measuring the extent of athereosclerosis or restenosis as compared to control treated animals.~~

~~12. (Original) The process of claim 11, wherein said PDE4 is PDE4D.~~

~~13. (Original) The process of claim 12 wherein the PDE4D is PDE4D5 or PDE4D7.~~

~~14. (Original) The process of claim 12 wherein the PDE4D is PDE4D7.~~

~~15. (Original) The process of any of claims 11 to 14, wherein the compound is for the therapy of Peripheral Arterial Occlusive Disease.~~

~~16. (Original) A compound identified by the process of any one of claims 6 to 15.~~

~~17. (Original) A pharmaceutical composition comprising a compound of claim 16 and a pharmaceutically acceptable carrier.~~

~~18. (Original) Use of a compound of claim 16 for the preparation of a medicament for th treatment of atherosclerosis, restenosis.~~

~~19. (Original) The use of claim 18, wherein said compound is used for the preparation of a medicament for the treatment of Peripheral Arterial Occlusive Disease.~~

~~20. (Original) The compounds, processes, uses and composition substantially as hereinbefore described, especially with reference to the foregoing examples.~~

21. (New) A method for the screening and identification of a compound which inhibits atherosclerosis or restenosis comprising the use of PDE4 as a target.

22. (New) The method of claim 21 wherein the PDE4D selected from the group consisting of PDE4D, PDE4DS and PDE4D7.

23. (New) The method of claim 22, wherein the PDE4 is PDE4D7.

24. (New) The method of claim 21 further comprising increasing the activation or inhibition of the phosphodiesterase activity of PDE4 by the compound.

25. (New) The method of claim 24, wherein the compound is an inhibitor of PDE4.

26. (New) The method of claim 25, wherein the PDE4 is selected from the group consisting of PDE4D, PDE4D5 and PDE4D7.

27. (New) A process for identifying and obtaining a compound for therapy of atherosclerosis, or restenosis, said process comprising administering a compound suspected to be an activator or inhibitor of PDE4 to a non-human animal in which atherosclerosis or restenosis is induced, and measuring the extent of atherosclerosis or restenosis as compared to control-treated animals.

28. (New) The process of claim 27, wherein said PDE4 is PDE4D.

29. (New) The process of claim 28 wherein the PDE4D is selected from the group consisting of PDE4D5 or PDE4D7.

30. (New) The process of claim 28 wherein the PDE4D is PDE4D7.

31. (New) The compound of claim 21.

32. (New) The compound of claim 25.

33. (New) The compound of claim 27.

34. (New) A pharmaceutical composition comprising the compound of claim 32 and a pharmaceutically acceptable isomer.

34. (New) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 34 to a subject having PAOD.

35. (New) A pharmaceutical composition comprising the compound of claim 27 and a pharmaceutically acceptable isomer.

36. (New) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 35 to a subject suffering form atherosclerosis or restenosis.